Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip

Vertex Pharmaceuticals' (VRTX -9.39%) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. However, Vertex's shares plunged after the company announced its first-quarter results on Monday. Should investors throw in the towel on Vertex? I don't think so. Instead, the sell-off presents a fantastic opportunity to double up on this big biotech innovator. Dissecting Vertex's bad news The main bad news with Vertex's Q1 results was that the company ...